US FDA Approves Reduced Monitoring Time for First 2 Doses of Imdelltra
The US Food and Drug Administration (FDA) has approved reduced monitoring time for the first 2 doses of Imdelltra, supporting broader community access for patients with extensive-stage Small Cell Lung Cancer (SCLC).
Community Oncology | 15/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy